/

Società

Pu

Non verificato

PureTech Health plc

Di cosa scriviamo

BiotecnologiaFarmaceuticaMedicina - VarieSaluteScienza

71 comunicati stampa

Guarda tutti i comunicati

29/10/2026

Salute

Sanità

Medicina - Varie

Scienza

Farmaceutica

Biotecnologia

Mercato del lavoro

PureTech Founded Entity Celea Therapeutics Appoints Paul Audhya, MD, MBA, as Chief Medical Officer

Fonte

PureTech Health plc

Emittente

1.00

0

26/10/2026

Scienza

Biotecnologia

Farmaceutica

Oncologia

Salute

Igiene alimentare

Medicina - Varie

Eventi

Industria

PureTech Presents Phase 1b Results for LYT-200 in Relapsed/Refractory (R/R) High-Risk Myelodysplastic Syndromes (HR-MDS) and Acute Myeloid Leukemia (AML) at ESMO 2026

Fonte

PureTech Health plc

Emittente

1.00

0

19/10/2026

Scienza

Biotecnologia

Farmaceutica

Oncologia

Sanità

Salute

Medicina - Varie

Industria

Eventi

PureTech Announces Presentation of Phase 1b Results for LYT-200 in Relapsed/Refractory (R/R) High-Risk Myelodysplastic Syndromes (HR-MDS) and Acute Myeloid Leukemia (AML) at ESMO 2026

Fonte

PureTech Health plc

Emittente

1.00

0

09/10/2026

Eventi

Industria

Scienza

Biotecnologia

Farmaceutica

Salute

Psichiatria

Medicina - Varie

PureTech Founded Entity Seaport Therapeutics Presents Additional Pharmacokinetic Data from Phase 1 Clinical Trial of GlyphAgo™ at the 39th European College of Neuropsychopharmacology (ECNP) Congress

Fonte

PureTech Health plc

Emittente

1.00

0

07/10/2026

Industria

Psichiatria

Salute

Medicina - Varie

Scienza

Farmaceutica

Biotecnologia

PureTech Founded Entity Seaport Therapeutics Announces First Patient Dosed in Phase 2a Clinical Trial Evaluating GlyphAgo™ in Patients with Generalized Anxiety Disorder and Sleep Disturbance

Fonte

PureTech Health plc

Emittente

1.00

0

21/09/2026

Multimedialità

Mercato del lavoro

Industria

Oncologia

Psichiatria

Salute

Igiene alimentare

Medicina - Varie

Farmaceutica

Biotecnologia

PureTech Announces Successful End-of-Phase 1 Meeting with U.S. Food and Drug Administration (FDA) and Receipt of Fast Track Designation for LYT-200 in Relapsed/Refractory (R/R) High-Risk Myelodysplastic Syndromes (HR-MDS)

Fonte

PureTech Health plc

Emittente

1.00

0

09/09/2026

Industria

Biotecnologia

Psichiatria

Salute

Farmaceutica

Medicina - Varie

PureTech Founded Entity Seaport Therapeutics Reports Positive Topline Results from Phase 1 Driving Simulation Trial of GlyphAllo™ in Healthy Volunteers

Fonte

PureTech Health plc

Emittente

1.00

0

04/09/2026

Web e Social Network

Telefonia e Varie

Finanza

Mercato azionario

Biotecnologia

Farmaceutica

Salute

PureTech Health: Notice of Half-Yearly Results

Fonte

PureTech Health plc

Emittente

1.00

0

13/07/2026

Industria

Salute

Medicina - Varie

Scienza

Farmaceutica

Biotecnologia

PureTech Founded Entity Celea Therapeutics Doses First Patient in Global Phase 3 SURPASS-IPF Trial Evaluating Deupirfenidone for the Treatment of Idiopathic Pulmonary Fibrosis (IPF)

Fonte

PureTech Health plc

Emittente

1.00

0

02/07/2026

Industria

Scienza

Igiene alimentare

Medicina - Varie

Biotecnologia

Sanità

Salute

Farmaceutica

PureTech Founded Entity Celea Therapeutics Completes $180 Million Financing to Advance Deupirfenidone as a Potential New Standard of Care to Treat Idiopathic Pulmonary Fibrosis (IPF)

Fonte

PureTech Health plc

Emittente

1.00

0

Seguaci

0

Compatibilità

0